Price
No data yet.
Social Signal Score
Revenue
$24.2KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christer Rosen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Beta
- 1.96
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -23.07
Financials
Revenue
$24.2K-97.6%Net Income
$-2.27MEBITDA
$-2.74MFree Cash Flow
$-2.29MEPS (diluted)
$-4.08Shares Outstanding (diluted)
557.6K+378.6%Operating Expenses
$2.76MCash & Debt
$1.52MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $21.8K | $-8.64M | $-18.75 |
| 2024 | $0.00 | $-2.44M | $-6.36 |
| 2023 | $0.00 | $-4.78M | $-10.50 |
| 2022 | $233.3K | $-4.96M | $-11.25 |
| 2021 | $638.0K | $-4.38M | $-33.00 |
| 2020 | $1.13M | $-1.65M | $-14.25 |
| 2019 | $0.00 | $-3.05M | $-26.25 |
Valuation
JUNShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80Social Signal Score
Mentions (1)
- Newsglobenewswire.com·1d ago·Negative
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering.
View source ↗
Earnings
Wed, Dec 2(in 3 months)
Consensus estimate $-3.75 per share
Typical surprise -17.1% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-5.06 vs $-3.75miss
- Thu, May 21$-4.39 vs $-3.75miss
- Fri, Apr 3$-5.61 vs $-5.25miss
- Mon, Dec 22$-5.25 vs $-6.00beat
- Mon, Aug 18$-5.26 vs $-5.26beat
- Thu, May 15$-3.76 vs $-2.26miss
Estimates and results for JUNS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by JUNS officers and directors.
- Bought
- $14k
- Sold
- —
21 trades
0 trades
- Silva Alison D.bought
- Silva Alison D.bought
- Silva Alison D.bought
- Rosen Christerbought
- Rosen Christerbought
- Silva Alison D.bought
- Silva Alison D.bought
- Silva Alison D.bought
79 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.